← Назад

Idiopathic pulmonary fibrosis

ORPHA:2032DiseaseMultigenic/multifactorialAdult

Ассоциированные гены (14)

SFTPA1
surfactant protein A1
Major susceptibility factor in
OMIM: 178630
DSP
desmoplakin
Major susceptibility factor in
OMIM: 125647
TERT
telomerase reverse transcriptase
Major susceptibility factor in
OMIM: 187270
TERC
telomerase RNA component
Major susceptibility factor in
OMIM: 602322
MUC5B
mucin 5B, oligomeric mucus/gel-forming
Major susceptibility factor in
OMIM: 600770
SFTPA2
surfactant protein A2
Major susceptibility factor in
OMIM: 178642
RTEL1
regulator of telomere elongation helicase 1
Major susceptibility factor in
OMIM: 608833
FAM13A
family with sequence similarity 13 member A
Major susceptibility factor in
OMIM: 613299
STN1
STN1 subunit of CST complex
Major susceptibility factor in
OMIM: 613128
ATP11A
ATPase phospholipid transporting 11A
Major susceptibility factor in
OMIM: 605868
DPP9
dipeptidyl peptidase 9
Major susceptibility factor in
OMIM: 608258
PARN
poly(A)-specific ribonuclease
Major susceptibility factor in
OMIM: 604212
SFTPC
surfactant protein C
Major susceptibility factor in
OMIM: 178620
ABCA3
ATP binding cassette subfamily A member 3
Candidate gene tested in
OMIM: 601615

Фенотипы (20)

Очень частый (80–99%)1
HP:0006530Abnormal pulmonary interstitial morphology
Частый (30–79%)16
HP:0001063Acrocyanosis
HP:0002020Gastroesophageal reflux
HP:0002110Bronchiectasis
HP:0002206Pulmonary fibrosis
HP:0002875Exertional dyspnea
HP:0012378Fatigue
HP:0012735Cough
HP:0025175Honeycomb lung
HP:0025179Ground-glass opacification on pulmonary HRCT
HP:0025390Reticular pattern on pulmonary HRCT
HP:0030830Crackles
HP:0031631Subpleural honeycombing
HP:0031950Usual interstitial pneumonia
HP:0032341Reduced forced vital capacity
HP:0045051Decreased DLCO
HP:0100759Clubbing of fingers
Периодический (5–29%)3
HP:0003546Exercise intolerance
HP:0010444Pulmonary insufficiency
HP:0033367Orthodeoxia

Эпидемиология (17)

Point prevalence
1-5 / 10 000
Worldwide
Annual incidence
1-9 / 100 000
Worldwide
Point prevalence
1-5 / 10 000
Canada
Annual incidence
1-5 / 10 000
Canada
Point prevalence
1-9 / 100 000
Finland
Annual incidence
1-9 / 100 000
Finland
Point prevalence
1-9 / 100 000
France
Annual incidence
1-9 / 100 000
France
Point prevalence
1-5 / 10 000
Italy
Annual incidence
1-9 / 100 000
Italy
Point prevalence
1-9 / 100 000
Japan
Point prevalence
1-5 / 10 000
Korea, Republic of
Annual incidence
1-5 / 10 000
Korea, Republic of
Point prevalence
1-5 / 10 000
United Kingdom
Annual incidence
1-9 / 100 000
United Kingdom
Point prevalence
1-9 / 100 000
United States
Annual incidence
1-9 / 100 000
United States

Лекарства и терапия

Источник: Open Targets Platform (в реальном времени)

Клинические исследования

Источник: ClinicalTrials.gov (в реальном времени)

Внешние ресурсы